Thank you for joining us today. Please note, this event is being recorded. I will now turn the call over to Tram Bui, Halozyme's Vice President of Investor Relations. Please go ahead.

Thank you, Operator. Good afternoon, and welcome to Halozyme's Third Quarter 2026 Financial and Operating Results Conference Call. In addition to the press release issued today after the market closed, you can find a supplementary slide presentation that will be referenced during today's call in the investor relations section of our website. Leading the call will be Dr. Helen Torley, Halozyme's President and Chief Executive Officer, who will provide an update on our business, and Darren Snellgrove, our Chief Financial Officer, who will review our financial results and outlook. On today's call, we will be making forward-looking statements as outlined on slide two. I would also refer you to our SEC filings for a full list of risk and uncertainties. During the call, both GAAP and non-GAAP financial measures will be discussed. Certain non-GAAP or adjusted financial measures are reconciled with the comparable GAAP financial measures in our earnings press release and slide presentation. I will now turn the call over to Dr. Helen Torley and we will start on slide three.

Thank you, Tom, and good afternoon, everyone. I'm pleased to report another exceptionally strong quarter for Halosyme as more patients, physicians and health care systems experience the benefits of subcutaneous delivery within hands. This is reflected in the record total and royalty revenues. and operationally, we continue to demonstrate new growth opportunities resulting from our compounding platform engine, Enhance. In and post the quarter, we significantly expanded the Enhance opportunity with three current partners expanding their agreements to add four new target nominations. Additionally, three Enhance-enabled programs, one each from Pfizer, Insight and Ergenix, advanced into phase one development. and GSK plans to initiate a Phase 1b study of a subcutaneous formulation of Belantamab with Enhance. With this planned start, we are on track to achieve 13 Enhance programs in clinical development by year end. Importantly, we also advanced our two hyperconcentration technologies, Hypercon and AeroCon, the new name for SurfBio, moving these closer to clinical testing. All of this contributed to the record total revenue, royalty revenue and adjusted EBITDA for Q3. Total revenue increased 39% year-over-year to $493 million, driven by royalty revenue, which increased 44% to a record $341 million. These results reflect the continued growth of our established commercial partner product portfolio and the growing contributions from the newer launches, which is resulting in a diversified and growing set of royalty revenue streams. Profitability remained strong during the quarter, with adjusted EBITDA of $336 million and an adjusted EBITDA margin of 68%, reflecting our disciplined execution. Based on this strength, we are raising our full year 2026 financial guidance. Darren will be discussing this in greater detail. Turning to slide four, let me now say a few more words about how we are increasing the enhanced opportunity through expanded agreements and new nominations by current partners. Three current enhanced partners expanded their collaborations and nominated four additional targets. Argenix expanded their agreement to include two additional exclusive targets, bringing the total to eight. Infect expanded and added one additional target to evaluate subcutaneous axolitumab. And in October, Johnson & Johnson added an additional oncology target to its longstanding enhanced collaboration. Collectively, these four new nominations expand the opportunity, further diversify our partnered pipeline, and add new potential sources of milestone and royalty revenue. Let me now move to slide five, and I'll provide some performance highlights on our commercial enhanced portfolio. D'Arcelic Subcutaneous, Fivegard Hyatulo and Fezgo all continue to demonstrate strong royalty revenue growth. In addition to, and on top of this, Ocrevus Zenovo, Obdivo QVantage and Ribrovent Faspro are adding increasingly meaningful royalty revenues. Enhance provides a competitive advantage for our partners by improving convenience, reducing administration time, and in some cases, improving the safety and tolerability profile compared to the IV treatment. For multiple partner products, these benefits are resulting in strong growth as the SC enables new sites of care and increased access to and for patients. I'll begin with highlights on the newer launch products. Roche continues to report strong momentum for subcutaneous ocreviscinoval, with approximately 56,000 patients globally now receiving the 10-minute subcutaneous formulation, an increase of about 12,000 patients since the first half of the year. Global conversion from ocrevisc IV to subcutaneous has now exceeded 20%, with adoption driven by both conversion and, importantly, new patients starting on ocreviscinoval. Roche noted on their third quarter call that approximately 50% of the Ocrevus-Senova starts are patients naive to Ocrevus treatment. This, I believe, demonstrates expansion of Ocrevus-Senova into community and more rural treatment settings where IV capacity can be limited. Roche continues to expect high single-digit Ocrevus growth in 2026 and 9 billion Swiss francs or approximately $11 billion in peak franchise sales by 2029. At just over 20% conversion today and with royalty revenues to at least 2034, this represents a large opportunity for Halazan. I'll move now to Bristol Myers Squibb and Updivo QVantage. On its third quarter call, BMS reported that approximately 17% of the Opdivo IV business has already converted to Opdivo QVantage, which is the subcutaneous formulation, with uptake occurring across multiple tumor types. Importantly, they also commented that conversion is tracking towards the higher end of its expectation for 30 to 40% of the IV business to ultimately convert to the subcutaneous formulation. SC administration within HANZ is delivering meaningful benefits for patients and physicians, including improved practice efficiency and a more convenient treatment experience. With durable royalties projected for many years and significant conversion ahead, this also represents an attractive growth royalty stream. Johnson & Johnson's Riprovent Faspro is another exciting opportunity. J&J reported 63.5% growth of Riprovent plus Lecluse in the third quarter, driven by strong share gains in both first and second line lung cancer treatment, continued launch uptake across regions, and rapid adoption of the subcutaneous version, Riprovent Faspro. They further noted that they expect FDA approval of Riprovent Faspro in advance head and neck cancer by the end of 2026, which would expand the opportunity beyond lung cancer into another area of significant unmet need. Johnson & Johnson also highlighted that Rhypervent is one of their key newer products that is expected to contribute more meaningfully to future growth and have commented that this growth will be fueled by Rhypervent Faspro. This represents another growth royalty revenue stream for Helizine with royalty revenues projected to the late 2030s. I'll now move to Darzalex Subcutaneous, Baivkar, Hytrulo, and Fezgo. And I'll begin with Darzalex. J&J reported $4.2 billion in sales in the third quarter for Darzalex, reflecting operational growth of 15.6%. Virtually all of the Darzalex-reported sales are for the Darzalex subcutaneous version within hands. This strong performance was driven by continued share gains across all lines of therapy, including 10 points of share gain in the frontline setting, together with ongoing market expansion. With analysts now projecting sales of $21 billion in 2028, we are excited to support the continued growth and expansion of this exceptional product. I'll move now to Vivegard Hytrulo. Argenix reported total Vivegard sales of $1.7 billion in the quarter, impressive growth of 54% year-over-year and 13% sequentially. Argenix highlighted continued growth in both generalized myasthenia gravis and CIDP, which is driven by the Vivegard Hedrula pre-filled syringe that provides greater patient convenience and flexibility in how treatment is administered. A recent additional driver of growth is the approval for seronegative myasthenia gravis which is already broadening the prescriber base with approximately 10% of seronegative prescribers new to Vivegard. Further opportunity expansion is projected in 2027 with potential approvals in ocular and pediatric myasthenia gravis. And beyond myasthenia gravis and CIDT, Ergenix is seeking to expand into a new population of patients, those with immune-mediated necrotizing myositis, or IMNM, with a SBLA planned by year end. This is a high unmet need patient population, where Ergenix has estimated there are approximately 20,000 patients living with this disease in the United States alone. These opportunities reinforce the potential for Badgar Hatuno to continue expanding across indications, patient populations, and prescribers, delivering long-term growth and projected royalty revenues to Halosyme into the 2040s. Moving now to Roche's Fesco. In the third quarter, Roche reported that Fesco also continued to deliver strong performance, with global conversion reaching 59%, up five percentage points since mid-year. signaling continued strong adoption for a product that was launched six years ago in 2020. The continued conversion from Progetto reinforces the durability of Fezgo with royalties projected into the 2030s and the value of Enhance in enabling sustained adoption of subcutaneous therapies. Collectively, all six products are demonstrating the continued scalability and durability of Enhance. Our established products continue to deliver strong growth, our new launches are becoming increasingly meaningful contributors, and the ongoing clinical, regulatory, and commercial progress are providing multiple drivers for future revenue growth. Moving now to slide six. With the new study starts in the third quarter, we have significantly expanded our product development pipeline. Today, we have 12 enhanced programs in clinical development. three of which the partners have requested to keep confidential at this time. With GSK planning to initiate a Phase 1b study of a subcutaneous formulation of belantemab within hands, we're on track to reach 13 clinical stage programs by year-end 2026. Recent advancements to highlight are Pfizer's initiation of a Phase 1 study of Tilrecumig, their investigational potential first-in-class tri-specific antibody that simultaneously inhibits upstream and downstream drivers of type 2 inflammation. Also, INSIGHT's initiation of a phase 1 study evaluating a subcutaneous formulation of their first-in-class antibody designed to selectively target mutant caloreticulin. And finally, Argenix's evaluation of ARGX119, their first-in-class humanized agonist monoclonal antibody targeting musk. Importantly, multiple partners are moving programs from collaboration signing into the clinic rapidly within months of signing. This momentum is a strong reflection of a broader trend in biopharmaceutical companies focusing on subcutaneous administration. Subcutaneous delivery is now recognized not simply as a convenience feature, but as an important driver of patient preference Healthcare System Efficiency, Competitive Differentiation, and Market Expansion. This pace of execution, combined with attractive opportunities across oncology, immunologies, and multiple other therapeutic areas, represents a highly attractive set of opportunities for enhanced royalty revenue beginning in the 2029 plus period and extending well into the next decade. This is the compounding platform engine at work. Commercial success driving new partner demand, new agreements creating additional development programs, and those programs building the next wave of potential royalty revenue. An important additional benefit of our compounding platform engine is the continuous innovation that is generated as we work with partners across a growing range of molecules, formulations, and delivery challenges. I am pleased to report that collaboration patents have been obtained by our licensees for seven of the 10 launch products. and that collaboration patents are pending for the others. We continue to expect that new collaboration patents will be granted to protect our licensees' innovations as they generate new data from their clinical trials. Let me now move to MDase and our modified hyaluronidase IP portfolio. Halazan pioneered and invented the use of hyaluronidases for large volume subcutaneous delivery. On October 7th, 2026, The Specialized Dutch Patent Corps of The Hague rejected Merck's invalidity challenges against Helizyme's M-Days patent, EP622, and found Keytruda Culex to be infringing the patent. The Corps also found that there was no reasonable likelihood that EP622 will be declared invalid in the other relevant European Member States where EP622 is granted, and prohibited Merck's European Marketing Approval Holder from committing an infringement in Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland, and the Netherlands by manufacturing or causing to be manufactured, offering, putting on the market, or using to produce subcutaneous in those countries, or by importing it or holding it in stock for that purpose. Previously, in December of 2025, Halocime won a critical preliminary injunction in Germany for EP622. The Munich Regional Court ordered Merck to halt the launch and distribution of Keytruda Culex in Germany. And in February of 2026, the German Federal Patent Court issued a preliminary opinion in validity proceedings that were brought by Merck, finding that Halocime's EP622 patent is likely valid. Together, these rulings prevent Merck from launching Keytruda Culex in key European markets and prevent Merck from achieving the same adoption and trajectory of Keytruda Culex in Europe as they are doing in the United States. I want to underscore just how important these recent EU court decisions are in supporting the validity of our EP622 patent and supporting Helozyme's position as the pioneer and leader for innovating the use of human-derived hyaluronidases for large-volume subcutaneous administration. I'll now move to HYPERCON and ERICON, our hyperconcentration technologies. HYPERCON and ERICON are complementary technologies to ENHANCE that extend our leadership in subcutaneous drug delivery, expand our addressable opportunity, and will create additional long-term royalty opportunities for Halozyme. Each has been demonstrated to achieve stable formulations of biologic therapies at a concentration of approximately 500 milligrams per mL, which is three to four-fold what is commonly achieved. The resultant lower volume required can allow delivery using a small volume autoinjector at home or in the doctor's office with the potential to further improve the patient treatment experience. Today, five collaboration and licensing agreements have been signed for access to HYPERCON including the potential to use HyperCon with more than 20 potential targets or drugs. We are on track to complete the clinical supply for two partner products formulated with HyperCon in the first quarter of 2027 to support first half 2027 phase one trial initiations. In parallel, we're advancing the HyperCon formulation for a growing portfolio of development programs including both commercial stage and development stage assets with several programs originating from recently signed collaborations and others representing future collaboration agreement opportunities. Now a word on Ericon. We're on track with our plans for 2026, which continues to support New Deal signings in 2027 and clinical entry in the second half of 2028. With Halazan's deep expertise, established capabilities, and proven track record in drug delivery, Halozyme is the natural home for innovative drug delivery technologies. I'll now pass the call over to Darren, who will be discussing our financial results, updated outlook, and capital allocation.

Thank you, Helen. I'll start on slide seven. The third quarter was another exceptional quarter for Halozyme. We delivered record royalty in total revenue, strong earnings growth, and substantial cash flow generation. while continuing to advance our future growth opportunities. Our results reflect the increasing diversification of our royalty portfolio with continued outperformance of our established commercial products and growing contributions from newer launches. Combined with the ongoing advancement and expansion of our pipeline, this supports the long-term durability of our revenue. We also successfully completed a $1.5 billion convertible note offering on attractive terms. The transaction reflects the strength of our financial profile and confidence in our long-term outlook, while further strengthening our balance sheet. Turning to the third quarter results, total revenue increased 39% to $493 million, compared to $354.3 million in the prior year period. This performance was driven by robust royalty revenue growth and higher product sales. Moving to slide 8 for more details on royalty revenue. Royalty revenue increased 44% year-over-year to a record $341 million, reflecting continued strength across our commercial portfolio. Third quarter Darzalex royalty revenue increased 20% year-over-year to $153.5 million. Vivgard Royalties to Halozyme increased 89% year-over-year to $88.1 million. Fezgo royalty revenue increased 23% year-over-year to $34.3 million in the third quarter. Other royalty revenue increased 92% to $65.1 million, driven by growing contributions from Okrava-Sonovo, Obivo-Cuvantage, Ribravant-Farsborough, and Ticentric-Hybrisa. Moving to slide 9 for additional details on profitability in our balance sheet. Research and development expenses were $27.8 million compared to $17.3 million in the prior year period, reflecting continued investment in advancing our enhanced and next generation technology platforms. Selling general and administrative expenses were $58.2 million in the quarter. compared to $46.1 million in the prior year period. The increase in SG&A expenses was primarily due to an increase in consulting fees, including litigation costs related to Merck. That income increased 41% to $247 million from $175.2 million in the prior year period. Adjusted EBITDA increased 35% to $336.2 million from $248.2 million in the prior year period, driven by continued strong royalty growth. Gap diluted earnings per share was $2.01 compared to $1.43 in the prior year period, and non-gap diluted earnings per share was $2.39 compared to $1.72 in the third quarter of 2025. Moving to slide 10. Our capital allocation priorities are unchanged. We remain focused on investing in the highest return opportunities across Enhance, HyperCon, and Aerocon, maintaining a strong balance sheet, and returning excess capital to shareholders through a disciplined capital return framework. Consistent with this approach, we completed $400 million of share repurchases in 2026. We also remain focused on deleveraging, including addressing our 2027 and 2028 convertible notes and maturity. Our net leverage was 2.4 times. We ended the quarter with $1.08 billion in cash, cash equivalents, and marketable securities, and $3.3 billion of long-term debt, leaving us well positioned to fund our organic growth initiatives while maintaining significant financial flexibility. Beyond our organic investments, we will continue to evaluate selective strategic opportunities that complement our portfolio and meet our discipline criteria for strategic fit, durable value creation, and attractive returns. Moving to slide 11. Based on our performance through the first nine months, we are raising our 2026 financial guidance. We now expect total revenue of $1.86 billion to $1.925 billion, an increase of $20 million at the midpoint, representing growth of 33% to 38% over 2025. Within that, we now expect royalty revenue of $1.235 billion to $1.255 billion, up $12.5 million at the midpoint. representing growth of 42% to 45%. Royalties remain the engine of our business and the main driver of this raise. We now expect product sales of $525 million to $540 million, up $7.5 million at the midpoint. We are raising adjusted EBITDA to $1.24 billion to $1.29 billion, up $12.5 million at the midpoint. with our adjusted EBITDA margin unchanged at approximately 67%. Finally, we now expect non-GAAP diluted EPS of $8.75 to $9.05, up 8 cents at the midpoint. The updated outlook reflects the continued strength of our diversified royalty portfolio, substantial operating leverage, and strong cash generation. With that, I'll turn the call back to Helen.

Thank you, Darren. In closing, our third quarter performance demonstrates the strength of our compounding technology platform, Enhance, where the actions during and post this quarter added meaningful near and long-term value. Hypergon and Ergon share many similar features that will create two additional compounding platforms on top of Enhance. Let me leave you with four key takeaways. Firstly, our royalty portfolio continues to grow and diversify. Record royalty revenue and growing contributions from three more recently launched products demonstrate the increasing breadth and durability of our business. Secondly, demand for Enhance remains exceptionally strong. The expanded agreements with existing partners will add multiple new programs into the development portfolio with the potential to broaden the reach of Enhance and create new royalty revenue streams. Thirdly, We're growing the next wave of royalty opportunities. We're on track to add 13 enhanced programs in clinical development by year end. Hypergon also remains on track for its first clinical trial start in the first half of 2027. And finally, our strong cash generation and financial flexibility provide additional capacity to invest in our technologies while maintaining a disciplined approach to capital allocation. Each new royalty stream, future launch opportunity and partnership adds another layer of growth on top of the foundation we have already built. I thank you all for your time today and operator, you can now open the call for questions.

We will now begin the question and answer session. If you would like to ask a question, please press star one to raise your hand. To withdraw your question, press star one again. We ask that you pick up your handset when asking a question to allow for optimum sound quality. If you are muted locally, please remember to unmute your device. Please stand by while we compile the Q&A roster. Your first question is from Jason Butler with Citizens JMP. Your line is now open. Please go ahead.

Hi. Thanks for taking the questions and congrats on the quarter. Helen, now that you're several quarters past the last two acquisitions, what do you think your capacity is to bring in more synergistic technologies, and what's your kind of perspective on priority there? And then I have a follow-up, thanks.

Yeah, if it's okay, Jason, I'll ask Darren to address that.

Yeah, thanks for the question, Jason. So for M&A, what I'd say is that our two recent acquisitions, Hypercon and Ericon, are progressing well, and so those are important growth drivers there. Thank you for joining us. something that could extend our royalty duration or strengthen the long-term revenue outlook. And obviously it needs to meet the appropriate return threshold. So we're definitely interested in technology that complements our platforms that can be deployed through scalable partnerships. And so that's really what we're looking for. Great.

Thank you. And then in terms of the hyperconcentration technologies, When you're speaking to prospective partners, what are they looking for in terms of technical proof of concept to move forward with a program? And when do you think we'll have the initial data from established partnerships that could provide that initial proof of concept?

Yeah, I think there's two kind of elements of proof of concept, Jason, to think about. One is the actual formulation. Can you formulate the product into a hyper-concentrated product? And as you know, we've got multiple examples and very successful examples of doing that up to 500 milligrams per ml. What we're finding is for some companies, they want to see it first, and other companies, they will accept the fact it's going to be very possible based on the wealth of data we already have. So I think that's One. And on the call I mentioned we've got multiple people in feasibility testing. Some of them are partners who signed before. The early development testing does encompass that formulation testing. Some of that is our current partners and some of it is people who want to get that data before they move forward to a new agreement. So we actually have a little bit of a pipeline of potential future agreements in that group of companies who are testing the formulation. I think the next proof of concept is The clinical proof of concept, the companies that are most advanced and we expect to be in the clinic in the first half of 27 have done the preclinical data. They've done all of that testing they can do. The next real step that they want to see is the clinical data. And so we're excited to be supporting them and moving forward to these phase one studies that will evaluate PK, local tolerability, things like that. So those would be the two things, but everything is advancing exactly as we had expected, and we're looking forward to starting the clinical studies in 27. Great.

Thanks for taking the questions.

Your next question is from Michael DeFiore with Evercore ISI. Your line is now open. Please go ahead.

Hey guys, thanks so much for taking my question and congrats on all the continued progress. Another question for me on HyperCon. Helen, what's the most important assumptions driving the $1 billion HyperCon royalty opportunity? And how much of that opportunity depends on established molecules just undergoing a formulation bridge versus investigational molecules that still need to demonstrate efficacy? Thank you.

Yeah, as we put out that projection that we can achieve a billion dollars, we were looking at an expectation of having five to seven products that would be in the clinic before the mid-2030s for that, Mike. And that does include... Thank you. Your next question is from Mitchell Kapoor with HC Wainwright. Your line is now open. Please go ahead.

This is Amidon from Mitchell. Thank you for taking our question. Congrats on a strong quarter. So for subcutaneous abalantamab, is the Phase 1b study designed primarily to establish peak comparability? Or are you also looking at peak exposure and how that improves safety? And I think one thing that we're interested in is like which toxicities do you believe could improve? And I have a quick follow-up. Thank you.

Yes, I don't believe GSK has posted a lot of details with regard to this study, so what I will be able to do is just speak in generalities about where we believe that Enhance is going to be able to be impactful with antibody drug conjugates. Phase I studies often evaluate the pharmacokinetics, and that's exactly what I would expect in this case. I do believe we'll be looking at the absorption profile, identifying is the Cmax coming down within hands versus perhaps what's historically been seen with IV, but also what is the overall exposure which does correlate generally very well with efficacy. So that in general terms is what we would expect for them to be looking at. Again, speaking in generalities, we're talking with broad partners, CMAX related toxicities can be anything from low white cell counts to GI distress to even ocular challenges as well. So each ADC that we work with is going to be different in terms of what the partner is seeking to mitigate potentially Got it. Thank you.

And I guess with additional targets being committed to existing partners, what obligations or what are the dynamics and deadlines accompanying enhanced exclusivity? When can HelloSign recover a target, for example, if a partner does not advance it?

Yeah, we've been in a very fortunate position that most of our partners, when they take exclusive targets, have advanced them or are advancing them. You know, there have been instances rarely over the years where perhaps a product has not progressed in the clinic or had the efficacy that was expected. And I will say in those instances, as soon as the company made a decision not to move forward with that target, they have returned it to Halazine. That's generally the structure of our agreements.

Got it. Thank you. Your next question is from Sean Lehman with Morgan Stanley. Your line is now open. Please go ahead.

Hi, Helen and team. Congratulations on the numbers and hope everyone's well. Helen, on slide six, when you're talking through those new products, new pipeline products, which are largely in phase one, I mean, how should we think about those as potential contributors post the commencement of reduced royalty rates? I assume some of these partners, the royalty rate reduces in line with some of your existing marketed products. And then I have a follow-up.

Yeah, the way we think about that portfolio, Sean, is very much one that what's exciting about it is the breadth of products that are in there. There is a mix of already established commercial products, but we're also very proud to be working with partners who are trying to move forward through innovations in care and not just me-tos. And so if we, on the call, I happened to mention Pfizer's tri-specific direct increment which is going to make a big difference we believe in patients with type 2 inflammation. So think of it as an exciting and broad portfolio. The deal structures are all a little bit different and some of our more recent deals, some of which are represented on that chart. We have a deal structure where it starts in the Low single-digit royalties going up into the mid-single-digit royalties, but in that instance, there is a modest reduction in the royalty rate if there are no valid patents. It's a very wide range of opportunities, but the message we have is exciting products, big TAM represented by these products, Durable royalties, with many of them going into the 2040s we project, and not all of them having stepped in, depending on if they get co-formed patents, which we believe many of them will get. This is why we talk about the great value of our compounding platform engine, because we're able to just keep adding wave upon wave of attractive royalties.

Interesting. Thank you. I have a question on Keytruda QLX. So according to the FDA approval letter for Keytruda QLX, the finished product is manufactured and fueled by, I think it's BSP Pharmaceuticals in Italy, which appears to be the only FDA approved facility for this purpose. I think the October 7th bunch injunction prohibits Merck's subsidiary from manufacturing or arranging manufacturing in the affected countries, as well as facilitating infringement by its affiliates. I'm just wondering that the injunction does not appear to distinguish between manufacturing for sale in those countries and manufacturing for export elsewhere. Would it be right to potentially assume that it affects Merck's ability to supply QLX to the U.S. and other markets outside the scope of the injunction?

We can address the potential impact on U.S. supply. as we don't have full knowledge of Merck's worldwide supply chain. But let me just take a step back and talk about what the Dutch court prohibited just to provide a little bit of context and tell you where the prohibition is. So the ruling from the Dutch court did stop Merck's EMA holder and its affiliates from committing an infringement in multiple European countries, as you know, including, though, by the manufacturer or causing Keytruda Culex to be manufactured in those countries. Now, as you mentioned, we know that BSP Pharmaceutical in Italy is a manufacturer for Culex for Merck. The current prohibition by the court that's in place for Merck's EMA holder and its affiliates, we believe, does impact those entities' ability to supply Culex from BSP entity. regardless of the ultimate destination of the product. And that's an important distinction there. And I will say Halozyme has also taken some additional actions and has sued BSP directly for infringement of EP622. So it's clear around the EMA holder, its affiliates, and what we know about BSP Pharmaceutica cannot comment on U.S. supply.

Got you. Extremely helpful on both questions. I appreciate it.

Your next question is from Dave Reisinger with Leerink Partners. Your line is now open. Please go ahead. Hi there, Dave. Your line is now open. You can go ahead with your question.

Sorry about that. So thanks very much for all the updates today and nice to see the progress. I guess I wanted to start on HyperCon. So Helen, could you just comment on whether there's any change today in the expected timing of two potential phase one starts in 2027? I think you mentioned The first half of 27, I don't know if both were previously expected to start in the first half. I just can't recall. And then second, with respect to, so one other HyperCon question, then I have one more, please. So the second HyperCon question is, could you talk about scale up? I know that it's been somewhat challenging to scale up HyperCon. Could you address that, please? Thank you.

Yeah, Dave, there is no change recently in our timeline of the expectation of when we would have the first clinical starts. Much earlier this year, we had stated that we expected now that the first clinical starts would be in the first half of 2027, and that's where we're tracking, and I mentioned on the call, we are expecting to make our first clinical supplies for the first two partners. in the first quarter to support the starts during the first half of 2027. With regard to the scale-up, any novel project like this does come with the need to evolve it as you're going on, and I have to say we've been making very, very strong progress with that, and that's what gives me Thank you for joining us today. Once we have done that, we have to start thinking about commercial launch and commercial supply. And so that's where we're very hard at work at the moment, finding additional partners to be able to do that process. But we expect that to be a very straightforward process because the hard work happens between your bench and your first clinical scale-up. All that the commercial scale up will be will be a slightly bigger volume, but it'll use largely the unidentical process. So really pleased with the progress and success that we are having there and look forward to keeping you updated.

Great, thank you. And then the other one relates to the Merck litigation. So I think many observers have been surprised that Merck hasn't settled. with Halozyme to be able to introduce its subcutaneous Keytruda in Europe. And, you know, I'm guessing that if the company is having conversations with Merck that it may relate to not just European litigation, but also U.S. litigation. So my two questions are, first, Can you compare and contrast your success in Europe versus your lack of success to date in the U.S. and comment specifically on that patent that blocked Merck in Europe? And then second, where are you with respect to having conversations with Merck? Thanks very much.

Yeah, I'll take the second part first, David. We haven't engaged in any conversations with Merck and Obviously, if we did do that, we wouldn't be in a position to provide any updates on that. But let's talk about where we are in Europe. We're absolutely thrilled with the resounding win from the Dutch court, which not only found that Merck was infringing, and this was a final decision after a full trial, they were found to be infringing on October 17th, and they Importantly, the court also said at that time that there is no reasonable likelihood that EP622, which is that key European patent, will be declared invalid in any other relevant European member states where EP622 is granted. Now, why do I emphasize that? I emphasize that because that really supported the court's decision to have this broad restriction from launching in eight of the European markets. And as you know, we already have an injunction in Germany as well. This EP622 is distinct from the U.S. patent portfolio and we're very pleased with the recognition by the European and particularly the Dutch and German patent courts on the validity of our patent and the fact that we are being infringed. And it's important because as we look at Europe, those eight markets and nine markets including Germany, in our experience from the sub-Q market represent about 20% of total global royalties. So we think this was a very important win strategically for Halazine. If we move to the U.S., to date, yes, Merck has been successful in gaining initial rulings on our U.S. patents, which, as I say, are distinct. And we've received adverse validity decisions on multiple of our PGRs that were filed. However, we are very confident that as we move forward into an appeal process here, which will take likely until 2028, that we will prevail. There's a lot of facts behind that statement, Dave, but it really comes from us being the pioneer in this area, and we believe that the appeal court will recognize just how strong our case is in terms of that. So very different patent systems, different patents in each of these. We do expect over time we're going to reap the same success in the U.S. as we have seen in Europe to date.

Thank you. Your next question comes from Brendan Wiatrowski with TD Cowan. Your line is now open. Please go ahead.

I guess I think that's supposed to be me, Brendan. Sorry for the confusion there. But thanks for taking the questions. I appreciate all the color on, especially the progress, kind of the next wave of enhanced assets. And I did notice kind of higher bulk API sales for the enhanced enzyme itself this quarter, which presumably will continue to ramp, I guess, as more drugs move through the clinic, I guess, this and next year. But Helen, can you just remind us, how should we think about kind of the comparable revenue contribution from HyperCon? as those assets move into and through the clinic. I think it's more milestone-based rather than API sales, but I guess how material could those be next year as the first couple HyperCon drugs start phase one? And I guess just secondly, related to that, are there any updates on when you might expect kind of the third and fourth HyperCon drugs to enter the clinic after those first two start on the first half of next year? Thanks.

You're quite right, Brendan, that for HyperCon, we won't be seeing API revenue. We'll see a small amount of collaboration revenue as we do experiments and partners pay for that work and our FTEs, but it's not the same model in terms of the API, so don't expect to line an API. But the model is very similar to our enhanced and many more. There are escalating milestones. So phase three is usually substantially higher than a phase one milestone. There are meaningful milestones at approval and then milestones as products achieve certain sales thresholds. So very similar and it can, you're quite right, be a meaningful contributor to our milestone revenue over time. With regard to products three and four, I mentioned that we are very pleased with the progress we're seeing and how broad the development pipeline is. We don't have specific dates from those partners as to when they will be moving into the clinic, but we can say numbers three and four are getting teed up and we'll look forward to providing an update when those clinical start dates are more clear to us.

Great, thanks. And then if I could just quickly follow up, I know you've in the past, I think, flagged, I think, 13 new launches between 2029 and 2031. I guess, can you first confirm if that's still what we should expect in terms of the number and timing of that next wave? But then also, if the 13 enhanced drugs you're flagging here in the deck to be in the clinic by the end of this year, are those kind of the same 13 or if there's any other, you know, maybe new indications or hypercon included in that 29 to 31 timeframe? Thanks.

Yeah, the 13 products are all new molecular entities in terms of what we count. We actually will have other new indications launching, Brandon, particularly as an example on VibeGuard that continues to just add and expand. Those aren't on the list, so that is not considered. This is actual new products moving into the clinic. We have said yes, up to 13 of these will launch between 29, and I do believe it was more 2032, but it is going to be in that window if they follow, and we would expect them to, our usual timeline for development, which is anything from four and a half to five and a half years. So that's what's giving us that confidence in that window. Now, obviously, they have to advance in development, but up to 13 is exactly the number.

Got it. Sounds good. Thank you.

Your next question is from Jessica Fye with JP Morgan. Your line is now open. Please go ahead.

Hey, guys. Good afternoon. Thanks for taking my question. Maybe coming back to HyperCon, just to... You've mentioned for a couple quarters now that a HyperCon partner is evaluating the potential return of a target. Just talk us through, like, what are various reasons that partners return targets? And then the second one is, what's the viscosity that you're seeing with the HyperCon formulated products? This maybe just varies by product, but is there any upper bound that you want to stay under? And are you finding that you're able to do that thus far? Thank you.

With regard to, and I guess I'll talk broadly on this as to why a partner might choose to return a target. It could be that they may have decided not to develop that product. That's the most common reason, and I talked about that a little bit earlier, that that's happened over the years with Enhance. With regard to the specific statement on HyperCon, we really can't say any more about that. That program is actually progressing, and so we can't say more about that at this period of time. But generally, if a product doesn't progress in the clinic or didn't achieve the efficacy profile that a partner would want, and you may remember with our Bristol agreement, some of the earlier Immunology, Immune Oncology targets that were more novel didn't actually meet the clinical expectations and so BMS returned those targets when that was determined. So that is the most common reason that we see. The Hypercon team don't talk in terms of viscosity, but basically what I can say is we seek to have the injection strength be perhaps in the 40 to 50 newtons, which is the hand grip of a small child as an example. Many of our drugs, that is easily injectable by an adult, as you can imagine, but many of the drugs in Hypercon we expect to be actually being given by auto-injector Your next question is from Mohit Banzal with Wells Fargo. Your line is now open. Please go ahead.

Hi, this is Zhengxi from Moheg. Thanks for taking our questions and congrats on the quarter. I just have one question regarding the 2027 and the beyond. So shall we expect an update on the multi-year outlook in early next year as typical? And then I think you guys previously mentioned that the new three launches for Enhance together contribute around 80%. I'm sorry, grow about 80% sequentially in the second quarter. Just curious how much of that, you know, potential thousand legs royalty step down between 2029 and 30 could be offset by these new launches? And then I have a follow up question. Thank you.

Yeah, thanks for the question. So we do plan to give 2027 guidance and an update on our long range outlook when we report Thank you for joining us.

New waves that we're seeing, we continue to see strong growth in those products. For each of those, there's a lot of growth left. I highlighted some of it in my call, but just to mention, Obdivo Quantage is about 17% converted today. Bristol expects it to be 30% to 40% over the next several years. And for that to continue, as we have seen, that moving to sub-Q is very sticky in terms of share prices. For Okra vs. Zenovo, that's just about a 20% conversion today of what will be an $11 billion at market, so very exciting there as well. And then Rybarvant SubQ, annualizing out to about $1.3 billion, but J&J has projected at least $5 billion in shares there. So you're quite right in focusing on these being very meaningful contributors, but that's all the detail we can give you today.

Thank you. And I just have another question regarding the collaboration revenues. I think you guys maintain the four-year guidance of $110 million to $130 million versus roughly about $65 million so far has been kicked in. So shall we still expect the remaining revenue to be recognized in the fourth quarter or has some portion of it will be shifted to the 2027?

It's hard to predict exactly how the collaboration revenue is going to pan out, but we did guide to expect a little bit heavier weighting of that in the fourth quarter. So I think you can expect to see some more coming in in fourth quarter.